Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807895 | 0.87 | AKR1B1 (0.50) | PBRM1AKR1B1MAOAMAOBCASP1 | |
| SCHEMBL1347195 | 0.85 | AKR1B1 (0.58) | PBRM1AKR1B1IL4I1BRD4HSD17B10 | |
| SCHEMBL1810289 | 0.80 | PBRM1 (0.51) | PBRM1AKR1B1IL4I1BRD4HRH3 | |
| SCHEMBL23589273 | 0.80 | ALDH1A1 (0.48) | PBRM1AKR1B1IL4I1BRD4MAOA | |
| SCHEMBL31660699 | 0.79 | PBRM1 (0.58) | PBRM1AKR1B1IL4I1BRD4HRH3 | |
| SCHEMBL4818350 | 0.79 | PBRM1 (0.58) | PBRM1AKR1B1IL4I1BRD4HRH3 | |
| SCHEMBL7605245 | 0.79 | PBRM1 (0.53) | PBRM1AKR1B1IL4I1BRD4HRH3 | |
| SCHEMBL4812956 | 0.76 | PBRM1 (0.55) | PBRM1AKR1B1IL4I1BRD4HRH3 | |
| SCHEMBL1346675 | 0.75 | AKR1B1 (0.52) | PBRM1AKR1B1MAOAMAOBHSD17B10 | |
| SCHEMBL1477730 | 0.75 | PBRM1 (0.50) | PBRM1AKR1B1IL4I1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | PBRM1 1933/4885AKR1B1 2382/4885IL4I1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.